No connection

Search Results

BFRI vs GDTC

BFRI
Biofrontera Inc.
BEARISH
Price
$0.86
Market Cap
$10.0M
Sector
Healthcare
AI Confidence
92%
GDTC
CytoMed Therapeutics Limited
BEARISH
Price
$1.00
Market Cap
$11.8M
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
BFRI
--
GDTC
--
Forward P/E
BFRI
-3.72
GDTC
-6.67
P/B Ratio
BFRI
-3.85
GDTC
2.31
P/S Ratio
BFRI
0.27
GDTC
13.74
EV/EBITDA
BFRI
-0.65
GDTC
-2.73

Profitability

Gross Margin
BFRI
64.41%
GDTC
89.57%
Operating Margin
BFRI
-89.84%
GDTC
-535.25%
Profit Margin
BFRI
-47.28%
GDTC
0.0%
ROE
BFRI
-1191.73%
GDTC
-50.28%
ROA
BFRI
-64.91%
GDTC
-29.31%

Growth

Revenue Growth
BFRI
-22.5%
GDTC
46.9%
Earnings Growth
BFRI
--
GDTC
--

Financial Health

Debt/Equity
BFRI
--
GDTC
0.07
Current Ratio
BFRI
1.15
GDTC
5.17
Quick Ratio
BFRI
0.51
GDTC
3.14

Dividends

Dividend Yield
BFRI
--
GDTC
--
Payout Ratio
BFRI
0.0%
GDTC
0.0%

AI Verdict

BFRI BEARISH

BFRI exhibits severe financial distress, reflected in a Piotroski F-Score of 1/9 (indicating weak financial health) and a lack of Altman Z-Score data, which raises red flags for potential bankruptcy risk. The company reports massive losses with a -47.28% profit margin, negative ROE (-1191.73%), and declining revenue (YoY -22.50%). Despite a strong gross margin (64.41%), operational inefficiencies and negative cash flows undermine sustainability. The stock trades at a deep discount (Price/Sales: 0.27), but this is not a value signal—rather, it reflects deteriorating fundamentals and investor skepticism. Analysts' 'strong_buy' recommendation appears disconnected from the underlying data.

Strengths
High gross margin (64.41%) suggests potential pricing power or low production costs
Recent 1-month price increase (+3.1%) indicates short-term momentum
Analyst consensus is 'strong_buy' despite poor fundamentals, suggesting potential catalyst expectations
Risks
Piotroski F-Score of 1/9 indicates extreme financial weakness and poor operational performance
Negative ROE (-1191.73%) and ROA (-64.91%) signal severe capital inefficiency and loss of shareholder value
Consistent earnings misses in the last 4 quarters (0/4 beats, average surprise -88.35%) reflect deteriorating execution
GDTC BEARISH

GDTC exhibits a fragile financial profile characterized by a Piotroski F-Score of 4/9, placing it in the 'stable' but lower-tier health category. While the company maintains strong liquidity (Current Ratio 5.17) and very low debt, these are overshadowed by a catastrophic operating margin of -535.25% and a total lack of profitability. The technical trend is severely bearish (0/100), with the stock price having declined over 63% in the last year and 75% over five years. Despite positive revenue growth, the valuation remains disconnected from fundamentals, trading at a high Price/Sales ratio of 13.74 without a path to earnings.

Strengths
Strong liquidity position with a Current Ratio of 5.17
Very low leverage (Debt/Equity of 0.07)
High Gross Margin (89.57%) typical of high-potential biotech
Risks
Extreme operational inefficiency with an operating margin of -535.25%
Severe multi-year price erosion (-75% over 3-5 years)
Micro-cap volatility and lack of institutional analyst coverage

Compare Another Pair

BFRI vs GDTC: Head-to-Head Comparison

This page compares Biofrontera Inc. (BFRI) and CytoMed Therapeutics Limited (GDTC) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI
Markets
Profile